NASDAQ:HRMY Harmony Biosciences Q3 2025 Earnings Report $27.05 +0.46 (+1.73%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$27.35 +0.30 (+1.11%) As of 10/7/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Harmony Biosciences EPS ResultsActual EPSN/AConsensus EPS $0.83Beat/MissN/AOne Year Ago EPSN/AHarmony Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHarmony Biosciences Announcement DetailsQuarterQ3 2025Date11/4/2025TimeBefore Market OpensConference Call DateTuesday, October 28, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Harmony Biosciences Earnings HeadlinesHarmony Biosciences (HRMY): Assessing Valuation After RECONNECT Trial Disappointment for ZYN002 in Fragile X SyndromeOctober 2, 2025 | finance.yahoo.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives $45.50 Average Price Target from BrokeragesOctober 2, 2025 | americanbankingnews.comMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works. | American Alternative (Ad)Harmony Biosciences Holdings (HRMY) Price Target Decreased by 12.03% to 45.44October 1, 2025 | msn.comH.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 SetbackSeptember 30, 2025 | msn.comEquities Analysts Set Expectations for HRMY Q3 EarningsSeptember 30, 2025 | americanbankingnews.comSee More Harmony Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Harmony Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harmony Biosciences and other key companies, straight to your email. Email Address About Harmony BiosciencesHarmony Biosciences (NASDAQ:HRMY) is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments. The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. WAKIX was granted approval in August 2019 following pivotal Phase III clinical trials demonstrating its efficacy and tolerability profile. Harmony Biosciences has established a commercial infrastructure across the United States to support patient access, education, and ongoing research into expanded indications. In addition to its marketed therapy, Harmony Biosciences maintains a clinical development program to evaluate pitolisant in other sleep disorders and cognitive conditions, leveraging its expertise in histaminergic modulation. The company collaborates with academic institutions, patient advocacy groups, and specialty pharmacies to facilitate real‐world data collection and to enhance support services for patients and healthcare providers. Harmony continues to explore strategic partnerships and licensing arrangements to extend its reach into international markets. Harmony Biosciences is led by President and Chief Executive Officer Joseph P. Woody, whose leadership team brings together experience in specialty pharmaceuticals, regulatory affairs, and commercial operations. With a focus on patient‐centric innovation and long‐term value creation, Harmony Biosciences aims to address unmet needs in rare disease communities while expanding its pipeline and geographic footprint.View Harmony Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
